Revenue segments as reported by the company.

Immunology

Hematologic Oncology

Aesthetics

Neuroscience

Eye Care

Women's Health

Other Key Products

All other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Acquired in-process research and development

Other operating expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

AbbVie

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AbbVie surpasses Q4 earnings forecast, eyes growth amid challenges

AbbVie's strong performance in Q4 2022 exceeded expectations, driven by key products like SKYRIZI and RINVOQ. Despite challenges in revenue and HUMIRA erosion, the company is focused on innovation and growth opportunities. Strategic investments in R&D and BD aim to navigate market dynamics and drive future success.

AbbVie surpasses Q1 expectations, eyes international growth amid challenges

AbbVie's Q1 2023 performance exceeded expectations, driven by key product sales and strong international results. While facing challenges in the U.S. market and inflationary pressures, the company remains confident in its long-term growth prospects and strategic initiatives.

AbbVie surpasses Q2 expectations, eyes revenue growth opportunities

AbbVie's Q2 2023 earnings call highlighted strong financial performance, successful execution in key therapeutic areas, and a promising outlook for revenue growth. Despite challenges like biosimilar competition and market dynamics, the company remains confident in its ability to deliver value and maintain growth.

AbbVie exceeds Q3 expectations, focuses on pipeline growth strategies

AbbVie's strong Q3 performance driven by key products and growth platforms, with positive trial results.
Challenges in aesthetics sales and Medicare drug pricing program offset by long-term growth opportunities.
Confidence in pipeline assets and strategic focus on combination therapies for future growth.
Maintaining strong market positions and investing in transformative therapies for competitive advantage.

AbbVie exceeds Q4 expectations, eyes growth through strategic acquisitions

AbbVie's stellar performance in Q4 2023 showcased strong sales growth, successful pipeline advancements, and strategic acquisitions. While facing challenges such as pricing pressures and safety concerns, the company is well-positioned to capitalize on opportunities in expanding its portfolio and driving growth through innovation and strategic partnerships.

AbbVie exceeds Q1 expectations, raises full-year guidance on strong sales growth

AbbVie's Q1 performance exceeded expectations, with strong sales growth in key products. The company raised full-year guidance and remains confident in maintaining good access for its brands. Challenges in aesthetics sales and inventory management are being addressed for future growth.

AbbVie reports robust Q2 results and raises 2024 guidance

AbbVie's strong Q2 performance, raised guidance, and strategic acquisitions highlight its growth trajectory.
Despite near-term challenges, the company's focus on key growth areas positions it for long-term success.
Investments in innovation and market expansion underscore AbbVie's commitment to sustained growth.
Overall, AbbVie's performance in Q2 2024 reflects a resilient and forward-looking approach to business.

AbbVie reports strong Q3 performance, raises guidance and dividend

AbbVie's Q3 2024 performance showcased robust sales growth, increased dividend, and raised revenue guidance, reflecting financial strength and market leadership.
The company's focus on long-term sustainability through investments, acquisitions, and pipeline advancements highlights a commitment to innovation and growth.
While facing challenges in clinical trial management and market competition, AbbVie remains well-positioned to leverage opportunities in diverse therapeutic areas for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Shares of AbbVie Inc (NYSE: ABBV) took a massive hit in early September after losing exclusivity for Humira – its treatment for rheumatoid arthritis. The stock has since recovered completely, and Wells Fargo says there's more to come in the coming months.

Wells Fargo sees a 35% upside in this pharma stock

NORTH CHICAGO, Ill., Dec. 9, 2021 /PRNewswire/ -- Allergan, an AbbVie (NYSE: ABBV) company, today announced that VUITY™ (pilocarpine HCl ophthalmic solution) 1.25%, the first and only eye drop approved by the U.S. Food and Drug Administration (FDA) to treat presbyopia, is now available by prescription in pharmacies nationwide.

VUITY™ (pilocarpine HCI ophthalmic solution) 1.25%, the First and Only FDA-Approved Eye Drop to Treat Age-Related Blurry Near Vision (Presbyopia), is Now Available

Amgen

VanEck Vectors Biotech ETF

Gilead Sciences

Novartis

Sanofi

We cover dividend stocks often at 24/7, as they provide investors with much better income streams than U.S.

Biotech Has Been Crushed: 5 Stocks to Buy Now That Pay Big Dividends

Enbridge

Fresenius Medical Care

Altria

Philip Morris

Fear has returned to Wall Street, with the market falling 4% in a matter of days as the Wall of Worry starts to take its toll.

Triple Your Retirement Income With These 6% Yielding Dividend Aristocrat Bargains

AbbVie Inc agreed to pay $200 million to settle claims by New York that its Allergan unit helped fuel an epidemic of opioid addiction in the state, shortly before jurors heard closing arguments from remaining defendant Teva Pharmaceutical Industries Ltd in a trial that has lasted more than five months.

AbbVie settles New York opioid case for $200 million as trial winds down

AbbVie's (ABBV) Rinvoq achieves primary and key secondary endpoints in the first phase III induction study in patients with Crohn's Disease.

AbbVie's (ABBV) Rinvoq Meets Goals in Crohn's Disease Study

Amazon

H&R Block

Tesla

Wells Fargo

As of Monday, five stocks that GuruFocus members are shunning over the Christmas holiday are Tesla Inc. ( TSLA , Financial), Amazon.com Inc. ( AMZN , Financial), H&R Block Inc. ( HRB , Financial), Wells Fargo & Co. Inc. ( WFC , Financial) and AbbVie Inc. ( ABBV , Financial).

5 Stocks GuruFocus Members Are Shunning for Christmas

AbbVie Inc (NYSE: ABBV) announced topline results from U-EXCEED, a Phase 3 induction study, of upadacitinib (45 mg once daily) in Patients with Crohn's Disease. The data achieved both primary endpoints of clinical remission and endoscopic response at week 12.

AbbVie's Upadacitinib Hits Primary Goal In Induction Study In Patients With Crohn's Disease

AstraZeneca

Moderna

Pfizer

Regeneron Pharmaceuticals

Should investors be watching these biotech stocks with all the current focus on the Omicron Covid variant?

5 Biotech Stocks To Watch In The Stock Market Today

AbbVie (ABBV) adds a heart-risk warning on the label of JAK inhibitor medicine, Rinvoq.

AbbVie (ABBV) Adds FDA-Issued New Warnings to Rinvoq's Label

NORTH CHICAGO, Ill., Dec. 6, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive top-line results from U-EXCEED, a Phase 3 induction study, showing upadacitinib (45 mg once daily) achieved both primary endpoints of clinical remission a,b  and endoscopic responsec at week 12.1 The U-EXCEED study enrolled patients with moderate to severe Crohn's disease who had an inadequate response or were intolerant to biologic therapy, with over 60 percent having previously failed two or more biologics.1 U-EXCEED is the first of two Phase 3 induction studies to evaluate the safety and efficacy of upadacitinib in adults with moderate to severe Crohn's disease.1  "The data from this first Phase 3 induction study in Crohn's disease suggest upadacitinib may help address the needs of patients suffering from this disease, as demonstrated in stringent endpoints such as endoscopic response," said Michael Severino, M.D.

Upadacitinib (RINVOQ®) Achieved Primary and Key Secondary Endpoints in First Phase 3 Induction Study in Patients with Crohn's Disease

AbbVie Inc (NYSE: ABBV) announced an update to the U.S. Prescribing Information and Medication Guide for Rinvoq (upadacitinib) for rheumatoid arthritis (RA).  The update follows a Drug Safety Communication (DSC) issued in September by the FDA following its final review of the post-marketing study, evaluating Pfizer Inc's (NYSE: PFE) Xeljanz (tofacitinib) in patients with RA.

AbbVie Adds New Warning To Rinvoq (JAK Inhibitor) Label For Rheumatoid Arthritis

Bristol-Myers

Eli Lilly

Merck

Roche Holding AG

Roche is optimally diversified both in terms of geography and in terms of portfolio. Pfizer and Eli Lilly are also broadly diversified but are more U.S.-centric companies. AbbVie, but also Merck are currently over-reliant on a single drug but this appears to be priced into the stocks accordingly.

Diversify, Diversify - Concentration Risks Of Several Pharma Companies

NORTH CHICAGO, Ill., Dec. 3, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced an update to the U.S. Prescribing Information and Medication Guide for RINVOQ® (upadacitinib) for the treatment of adults with moderate to severe rheumatoid arthritis (RA).

AbbVie Provides Update on RINVOQ® (upadacitinib) for the Treatment of Rheumatoid Arthritis in the U.S.

AbbVie Inc. (ABBV) Presents at 4th Annual Evercore ISI Virtual HealthCONx Conference (Transcript)

Fulgent Genetics

Teladoc

Shares of these companies are gift-wrapped for those with patience.

3 Stocks That Could Make You Richer in December (and Beyond)

AbbVie (ABBV) submits a regulatory application in the European Union, seeking approval for risankizumab (Skyrizi) for the treatment of Crohn's disease.

AbbVie (ABBV) Files for Skyrizi to Treat Crohn's Disease in EU

AbbVie Inc's. (ABBV) Management Presents at Piper Sandler 33rd Annual Virtual Healthcare Conference (Transcript)

Members of U.S. Congress are free to buy and sell stocks as long as the moves are disclosed within 45 days of the transaction. This practice has been controversial over the years, with members of Congress who make decisions on key policies and department spending often having an inside line on companies that could benefit.

2 Biotech Stocks A Congressman Is Betting On With Omicron Variant Emerging

ViacomCBS

AbbVie and ViacomCBS can provide investors a good mix of growth and dividend income.

2 Ridiculously Cheap Dividend Stocks To Buy for 2022

Abbott Labs

Johnson & Johnson

Medtronic

Walgreens

Just when you thought it was starting to look safer, yet another COVID-19 variant comes around.

5 Health Care Dividend Aristocrats to Buy for 2022 as Yields Plunge Once Again

NORTH CHICAGO, Ill., Nov. 30, 2021 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced it has submitted an application to the European Medicines Agency (EMA) seeking approval for risankizumab (SKYRIZI®, 600 mg intravenous (IV) induction and 360 mg subcutaneous (SC) maintenance therapy), an interleukin-23 (IL-23) inhibitor, for the treatment of patients 16 years and older with moderate to severe active Crohn's disease who have had inadequate response, lost response or were intolerant to conventional or biologic therapy.

AbbVie Submits Application for Risankizumab (SKYRIZI®) in Moderate to Severe Crohn's Disease to European Medicines Agency (EMA)

As an income investor, it can be difficult to find high-yield dividend stocks that can stuff your accounts with a growing amount of cash each year. AbbVie's payout ratio is positioned to improve from 41.1% this year to 40.3% next year despite its 8.5% dividend increase, which translates into a safe dividend with room to grow.

AbbVie: A High-Yielder That Can Flood You With Cash

Comcast

D.R. Horton

Gaming and Leisure Properties

Intel

Lowe's

Mastercard

UnitedHealth Group

Visa

Verizon

Walmart

Xilinx

Kiplinger Investing publishes opportune source-lists for investors online. Two recent billionaires stock-lists by Dan Burrows were published 6/1/21 and 9/9/21. 20 of the 37 billionaire-held stocks pay dividends. As of 11/21/21, the top-ten ranged 1.28%-5.77% by annual yield and ranged 18.52%-56.53% per broker-estimated price-target upsides.

1 To Buy Out Of 37 Billionaire Holdings In November

AbbVie offers an optimal combination of good current income, excellent financial safety, and strong secular support and growth.

News for AbbVie Stock (ABBV)